

Anti-D immunoglobulin

Section	Indications
Human immunoglobulins	Rh incompatibility reaction
Parenteral > General injections > IV: 250 µg in single-dose vial	
Parenteral > General injections > IM: 250 µg in single-dose vial	Maternal care for red cell antibodies

Anti-rabies immunoglobulin

Section	Indications
Human immunoglobulins	Rabies
Parenteral > General injections > IM: 150 IU per mL in vial	
Parenteral > Locoregional injections > Other: 150 IU per mL in vial	

Anti-tetanus immunoglobulin

Section	Indications
Human immunoglobulins	Tetanus
Parenteral > General injections > IM: 500 IU in vial	

C1 esterase inhibitor

Section	Indications
Plasma-derived medicines	Hereditary angioedema
Parenteral > General injections > IV: 500 IU in vial powder for injection	

Coagulation factor IX complex

Section	Indications
Coagulation factors	Therapeutic equivalent to coagulation factor IX, plasma-derived for
	Coagulation defects, purpura or other haemorrhagic or related conditions
	Therapeutic equivalent to coagulation factor IX, plasma-derived for
	Haemophilia B

Coagulation factor IX, plasma-derived

Section	Indications
Coagulation factors	Coagulation defects, purpura or other haemorrhagic or related conditions
Parenteral > General injections > IV: 500 IU in vial powder for injection; 1000 IU in vial powder for injection	Haemophilia B

Coagulation factor VIII, plasma-derived

Section	Indications
Coagulation factors Parenteral > General injections > IV: 250 IU in vial powder for injection; 500 IU in vial powder for injection; 1000 IU in vial powder for injection	Haemophilia A

Cryoprecipitate (not pathogen-reduced)

Section	Indications
Blood and blood components Injection: frozen liquid in bag or lyophilized powder in vial containing: -> 50 IU Factor VIII -> 100 IU vWF -> 140 mg clottable fibrinogen per unit	Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for Haemophilia A Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for Coagulation defects, purpura or other haemorrhagic or related conditions Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for Von Willebrand disease Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for Obstetric haemorrhage

Cryoprecipitate (pathogen-reduced)

Section	Indications
Blood and blood components Injection: frozen liquid in bag or lyophilized powder in vial containing: -> 50 IU Factor VIII -> 100 IU vWF -> 140 mg clottable fibrinogen per unit	Coagulation defects, purpura or other haemorrhagic or related conditions Obstetric haemorrhage Haemophilia A Von Willebrand disease

Dextran 40

Section	Indications
Plasma substitutes Injection: 6% injectable solution	Hypovolaemia

Dextran 70

Section	Indications
Plasma substitutes Injection: 6% injectable solution	Hypovolaemia

Fresh-frozen plasma

Section	Indications
Blood and blood components Parenteral > General injections > IV:	Blood transfusion without reported diagnosis

Normal immunoglobulin

Section	Indications
Human immunoglobulins Parenteral > General injections > IV: 5% protein solution; 10% protein solution Parenteral > General injections > IM: 16% protein solution Parenteral > General injections > SC: 15% protein solution; 16% protein solution	Primary immunodeficiencies Langerhans cell histiocytosis Mucocutaneous lymph node syndrome

Platelets

Section	Indications
Blood and blood components Parenteral > General injections > IV:	Blood transfusion without reported diagnosis

Polygeline

Section	Indications
Plasma substitutes Parenteral > General injections > IV: 3.5% injectable solution Parenteral > General injections > IV: 3.5% in solution	Therapeutic equivalent to dextran 70 for Hypovolaemia Hypovolaemia

Red blood cells

Section	Indications
Blood and blood components Parenteral > General injections > IV:	Blood transfusion without reported diagnosis

Whole blood

Section	Indications
Blood and blood components Parenteral > General injections > IV:	Blood transfusion without reported diagnosis